Strategic Overview

Clemedi develops Tuberculini, a targeted NGS solution for TB drug resistance testing.

Innovation Portfolio

Tuberculini
Category: DRUG RESISTANCE Stage: Commercial

Targeted next-generation sequencing platform for comprehensive Mycobacterium tuberculosis drug resistance profiling. Designed for central/reference laboratory use with high-throughput capabilities.

tNGS Sputum

Key Milestones

Tuberculini targeted NGS for drug resistance
RIF resistance: 95.5% sensitivity
Central-level capability
24-48 hour turnaround
Commercial availability